PDS Biotech Q2 FY26 net loss widens to $9.8 million; R&D expense falls 22.49% to $3.3 million - PDSB News | RalliesPDS Biotech Q2 FY26 net loss widens to $9.8 million; R&D expense falls 22.49% to $3.3 million
P
PDSB• Strategy shifts toward PDS0301
- Strategy refocus prioritizes tumor-targeted IL-12 program PDS0301; internal investment in PDS0101 stops, including ending VERSATILE-003 Phase 3.
Quarterly loss widens as expenses fall
- PDS Biotech posted a Q2 net loss of $9.8 million, or $0.18 a share, versus a loss of $9.4 million.
- R&D expense fell to $3.3 million from $4.2 million on lower clinical trial, manufacturing and personnel costs.
- Operating costs dropped to $6.5 million from $7.6 million; net interest expense climbed to $3.3 million from $1.8 million.
- Cash and equivalents were $5.6 million at June 30, 2026, down from $26.7 million at Dec. 31, 2025.
SINT
•
